Carvedilol Tablet, Film Coated
Product Images NDC 43063-129

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Carvedilol (NDC 43063-129). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

43063129 Label (43063129)

Label for Carvedilol USP 25 mg film-coated tablets, 180 count, from PD-Rx Pharmaceuticals, Inc. The label includes dosage strength, quantity, manufacturer information, a warning to keep out of reach of children, and prescription-only designation. It also contains reordering, lot, and expiration information (05/2023).*

FDA Label Image

Figure 1. Survival Analysis For Copernicus (intent-to-treat) (Carvedilol Fig1)

A survival analysis line chart titled 'Survival Analysis for COPERNICUS (Intent-to-Treat)', showing percentage mortality over 21 months. Two lines compare mortality between placebo and Carvedilol groups, with the placebo line showing higher mortality. A P-value of 0.004 is noted on the chart.*

FDA Label Image

Figure 2. Effects On Mortality For Subgroups In Copernicus (Carvedilol Fig2)

A horizontal forest plot titled 'Effects on Mortality for Subgroups in COPERNICUS.' It displays hazard ratios with confidence intervals for various patient subgroups grouped by characteristics such as gender, age, race, diabetes status, ischemic condition, heart rate, systolic blood pressure, and use of spironolactone. The x-axis ranges from 0.0 to 2.0, with a vertical dashed line at 1.0 indicating the reference hazard ratio.*

FDA Label Image

Figure 3. Survival Analysis For Capricorn (intent-to-treat) (Carvedilol Fig3)

A survival analysis line graph labeled 'Figure 3. Survival Analysis for CAPRICORN (Intent-to-Treat),' displaying percent mortality over 24 months. Two lines compare mortality rates for placebo and carvedilol groups, with the carvedilol group showing lower mortality. A p-value of 0.03 is noted on the chart.*

FDA Label Image

Figure 4. Effects On Mortality For Subgroups In Capricorn (Carvedilol Fig4)

A forest plot titled 'Effects on Mortality for Subgroups in CAPRICORN,' showing hazard ratios for different patient subgroups based on clinical characteristics such as age, gender, timing post-myocardial infarction, medication use, and comorbid conditions like heart failure, diabetes, hypertension, and heart rate. The hazard ratios are plotted with confidence intervals around a reference line at 1.0.*

FDA Label Image

Chemical Structure (Carvedilol Str)

Chemical structure of carvedilol, illustrating its molecular framework with identifiable groups including a methoxyphenyl and an indole-like bicyclic system, connected by a hydroxypropylamine side chain.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.